Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Gabriele Guardigli,
In around half of patients diagnosed with heart failure, a relatively preserved systolic function (LVEF>0.40) is found.
The diagnosis of heart failure with normal ejection fraction (HFNEF) requires three conditions to be satisfied: 1) signs or symptoms of heart failure; 2) normal LV function; 3) evidence of diastolic LV dysfunction.
Tissue Doppler or cardiac catheterisation provide evidence of diastolic dysfunction. Natriuretic peptides need to be combined with blood flow Doppler, LV mass index, LA volume index or presence of AF to provide evidence of diastolic LV dysfunction.
Treatment of diastolic heart failure is hampered by the absence of evidence for a specific drug that can reduce mortality and morbidity in these patients.
Theoretically, a number of treatments might benefit patients with HFNEF, but the development of treatment has been neglected until recently. To date we have no definitive data that any treatment improves outcome in HFNEF and no treatment is approved for this indication.
For example, blockers of the renin-angiotensin system, such as ACE-inhibitors, angiotensin receptor blockers (ARBs)and aldosterone antagonists are of particular interest, but strong evidence for their beneficial effect is still lacking and the results of some studies (CHARM-preserved with candesartan, PEP-CHF with perindopril and VALIDD with valsartan) were not positive.
Two large trials with RAAS blockade are ongoing, namely I-PRESERVE with irbesartan and TOPCAT with spironolactone and their results are expected soon. Many other interesting possibilities concern newer agents (alagebrium, ivabradine, ranolazine).
In my opinion, heart failure with normal ejection fraction is an interesting and important topic, but today, we still need to acquire more knowledge about the physiopathology, and we need specific clinical studies with adequate selection of patients to tailor therapeutic strategy for this indication.
Webcasts of Presentations available: W. Paulus , JJV Mc Murray
Heart Failure with Normal Ejection Fraction
This congress report accompanies a presentation given at the ESC Congress 2008. Written by the author himself/herself, this report does not necessarily reflect the opinion of the European Society of Cardiology.
© 2017 European Society of Cardiology. All rights reserved